Anzeige
Mehr »
Mittwoch, 14.01.2026 - Börsentäglich über 12.000 News
Gold auf Rekordhoch: Eine der spannendsten Gold-Stories 2026 steht ganz am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Singapur 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktueller Chart Singapur

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 

Aktien aus Singapur im Blickpunkt

Halozyme Therapeutics, Inc.: Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZEAgreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics...
► Artikel lesen
Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For RusfertideTOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX), Monday announced the submission of a New Drug Application regarding rusfertide for the...
► Artikel lesen
XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab- Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine...
► Artikel lesen
Takeda Canada: British Columbia Now Reimburses FRUZAQLATOKYO (dpa-AFX) - Takeda Canada announced that FRUZAQLA - fruquintinib capsules - will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer...
► Artikel lesen
Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia VeraTOKYO (dpa-AFX) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera...
► Artikel lesen
Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC TherapiesBEIJING (dpa-AFX) - Innovent Biologics (IVBXF, 1801.HK) announced that its global strategic collaboration with Takeda (4502.T, TAK) has officially closed and become effective following the satisfaction...
► Artikel lesen
Reliance Fined For Incorrect Availment Of Input Tax CreditMUMBAI (dpa-AFX) - Reliance Industries Limited (500325, RELIANCE) has received an order from the Deputy Commissioner of State Tax, Jamnagar, India imposing on the company a penalty of Rs. 1.11...
► Artikel lesen
Research and Markets: Europe Sodium-Ion Battery Analysis Report 2025: Market to Reach $1.49 Billion by 2035 from $50 Million in 2024, Driven by Sustainability, Energy Security, and Reduced Reliance on Imports - ResearchAndMarkets.comThe "Europe Sodium-Ion Battery Market: Focus on Application, Product, and Country Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe sodium-ion...
► Artikel lesen
Dividendenbekanntmachungen (13.08.2025) Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABN AMRO BANK NV  NL0011540547 - 0,54 EUR  ADCORP HOLDINGS LIMITED  ZAE000000139  0,5001 ZAR  0,0243 EUR  AERCAP HOLDINGS NV  NL0000687663  0...
► Artikel lesen